DDInter1139 DDInter262
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Picosulfuric acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Oxybenzone
Oxybenzone {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may lead to a major life threatening interaction when taken with Cabozantinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Cabozantinib
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Flurbiprofen may lead to a major life threatening interaction when taken with Cabozantinib
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Oxybenzone (Compound) and Oxybenzone (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib